Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry

JACC: Cardiovascular Interventions

Volumn 9, Issue 20, 2016, Pages 2097-2109

  Lee, Joo Myung ^a   Kang, Jeehoon ^b,c   Lee, Euijae ^b   Hwang, Doyeon ^b   Rhee, Tae Min ^b   Park, Jonghanne ^b   Kim, Hack Lyoung ^d   Lee, Sang Eun ^b   Han, Jung Kyu ^b   Yang, Han Mo ^b   Park, Kyung Woo ^b   Na, Sang Hoon ^b,e   Kang, Hyun Jae ^b   Koo, Bon Kwon ^b,e   Kim, Hyo Soo ^b,c  

^a Samsung Medical Center   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

chronic kidney disease; chronic renal failure; clinical outcomes; coronary artery disease; drug eluting stent(s); percutaneous coronary intervention

Indexed keywords

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL OUTCOME; CLINICAL PRACTICE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ELUTING STENT; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DEVICES; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; KAPLAN MEIER METHOD; KIDNEY; KIDNEY FAILURE, CHRONIC; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTHESIS DESIGN; REGISTER; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; TIME FACTOR; TREATMENT OUTCOME;

AGED; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; REGISTRIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84992734310     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.06.051     Document Type: Article

References (33)

1. 1 Cai, Q., Mukku, V.K., Ahmad, M., Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev 9 (2013), 331–339.
2. 2 Chan, W., Ivanov, J., Kotowycz, M.A., et al. Association between drug-eluting stent type and clinical outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention. Can J Cardiol 30 (2014), 1170–1176.
3. 3 Tsai, T.T., Messenger, J.C., Brennan, J.M., et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol 58 (2011), 1859–1869.
4. 4 Authors/Task Force m, Windecker, S., Kolh, P., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
5. 5 Shenoy, C., Boura, J., Orshaw, P., Harjai, K.J., Drug-eluting stents in patients with chronic kidney disease: a prospective registry study. PLoS One, 5, 2010, e15070.
6. 6 Palmerini, T., Biondi-Zoccai, G., Della Riva, D., et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 63 (2014), 299–307.
7. 7 Toutouzas, K., Patsa, C., Synetos, A., et al. The impact of new generation drug-eluting stent implantation on patients with chronic kidney disease and a single lesion in the proximal segment of the left anterior descending artery. Hellenic J Cardiol 52 (2011), 103–110.
8. 8 Ahmed, K., Jeong, M.H., Chakraborty, R., et al. Comparison of zotarolimus- and everolimus-eluting stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention. J Cardiol 64 (2014), 273–278.
9. 9 Tomai, F., Ribichini, F., De Luca, L., et al. Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease (RENAL-DES) Study. Circulation 129 (2014), 1104–1112.
10. 10 Inker, L.A., Astor, B.C., Fox, C.H., et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63 (2014), 713–735.
11. 11 American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care 37:Suppl 1 (2014), S14–S80.
12. 12 Coskun, U., Orta Kilickesmez, K., Abaci, O., et al. The relationship between chronic kidney disease and SYNTAX score. Angiology 62 (2011), 504–508.
13. 13 Latif, F., Kleiman, N.S., Cohen, D.J., et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. J Am Coll Cardiol Intv 2 (2009), 37–45.
14. 14 Choi, D.H., Park, K.W., Yang, H.M., et al. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol 149 (2011), 174–181.
15. 15 Otsuka, Y., Ishiwata, S., Inada, T., et al. Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry. Eur Heart J 32 (2011), 829–837.
16. 16 Miao, Y., Yu-Jie, Z., Zhi-Jian, W., et al. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents. Catheter Cardiovasc Interv 80 (2012), 361–367.
17. 17 Smits, P.C., Kedhi, E., Royaards, K.J., et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol 58 (2011), 11–18.
18. 18 Park, K.W., Chae, I.H., Lim, D.S., et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 58 (2011), 1844–1854.
19. 19 Kimura, T., Morimoto, T., Natsuaki, M., et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation 126 (2012), 1225–1236.
20. 20 Park, D.W., Kim, Y.H., Yun, S.C., et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 56 (2010), 1187–1195.
21. 21 Stone, G.W., Midei, M., Newman, W., et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299 (2008), 1903–1913.
22. 22 Stone, G.W., Rizvi, A., Newman, W., et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362 (2010), 1663–1674.
23. 23 Crimi, G., Leonardi, S., Costa, F., Adamo, M., Ariotti, S., Valgimigli, M., Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. Int J Cardiol 212 (2016), 110–117.
24. 24 Kaneko, H., Yajima, J., Oikawa, Y., et al. Role of arterial stiffness and impaired renal function in the progression of new coronary lesions after percutaneous coronary intervention. Cardiovasc Interv Ther 28 (2013), 56–62.
25. 25 Kato, K., Yonetsu, T., Jia, H., et al. Nonculprit coronary plaque characteristics of chronic kidney disease. Circ Cardiovasc Imaging 6 (2013), 448–456.
26. 26 Kashiyama, K., Sonoda, S., Muraoka, Y., et al. Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study. Int J Cardiovasc Imaging 31 (2015), 935–945.
27. 27 Morel, O., El Ghannudi, S., Jesel, L., et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 57 (2011), 399–408.
28. 28 Yazaki, Y., Iijima, R., Nakamura, M., Sugi, K., Relationship between renal function stage and clinical outcomes after paclitaxel-eluting stent implantation. J Cardiol 57 (2011), 61–68.
29. 29 Bangalore, S., Guo, Y., Samadashvili, Z., Blecker, S., Xu, J., Hannan, E.L., Revascularization in patients with multivessel coronary artery disease and chronic kidney disease: everolimus-eluting stents versus coronary artery bypass graft surgery. J Am Coll Cardiol 66 (2015), 1209–1220.
30. 30 Bae, E.H., Lim, S.Y., Choi, Y.H., et al. Drug-eluting vs. bare-metal stents for treatment of acute myocardial infarction with renal insufficiency. Results from Korea Acute Myocardial Infarction Registry. Circ J 75 (2011), 2798–2804.
31. 31 Sardi, G.L., Maluenda, G., Torguson, R., et al. Impact of diabetes mellitus on long-term clinical outcomes of patients on chronic hemodialysis after percutaneous coronary intervention. J Interv Cardiol 25 (2012), 147–155.
32. 32 Park, K.W., Lee, J.M., Kang, S.H., et al. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. J Am Coll Cardiol Intv 7 (2014), 471–481.
33. 33 Park, K.W., Kang, S.H., Kang, H.J., et al. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial. J Am Coll Cardiol 63 (2014), 2805–2816.